退化无支架主动脉生物瓣的再次干预:瓣中瓣经导管技术的角色
本研究评估2010至2015年间52例因无支架主动脉生物瓣衰败行再次干预的患者,由心脏团队分配25例再次手术、27例瓣中瓣经导管主动脉瓣植入(ViV-TAVI)。
要点
- 无支架主动脉生物瓣衰败的再次干预具有挑战性,需心脏团队个体化决策。
- ViV-TAVI适用于高危患者,但需警惕冠状动脉阻塞、器械移位等并发症。
- 再次手术适用于低危患者或需同期手术者。
核心结论
- 无支架主动脉生物瓣衰败的再次干预具有挑战性;ViV-TAVI适合高危患者但存在局限性和潜在并发症,再次手术适用于低危或需同期手术的患者。
研究设计与样本
- 回顾性研究,纳入2010至2015年52例连续患者(年龄72.3±9.7岁,EuroSCORE II 11.1±8.9%),因无支架主动脉瓣衰败行再次干预,由心脏团队分配25例再次手术、27例ViV-TAVI。
主要发现
- 瓣膜植入手术组全部成功(24%行根部替换),经导管组24例成功(93%经股动脉,56%球囊扩张式)。
- 手术并发症包括再次手术中主动脉夹层1例;ViV-TAVI中冠状动脉阻塞4例、器械移位3例、植入>1个瓣膜2例、血管入路部位并发症2例。
- ViV-TAVI在通气时间、输血需求和脓毒症发生率方面更优。
- 总体功能结果(94% NYHA I/II级)和超声心动图结果(指数化有效瓣口面积0.95±0.27 cm2/m2,平均跨瓣压差14±6.8 mmHg)良好;ViV-TAVI后主动脉瓣反流轻度和中度分别为2例和3例。
临床怎么用
- 心脏团队应根据年龄、EuroSCORE II、肺动脉高压、肾衰竭、内乳动脉桥通畅情况及是否需要同期手术等选择再次手术或ViV-TAVI。
- 高危患者可优先考虑ViV-TAVI,但需充分评估并防范冠状动脉阻塞等并发症。
- 低危患者或需同期手术者,再次手术仍是合理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study evaluates reinterventions for degenerated stentless aortic xenografts. METHODS: Between 2010 and 2015, 52 consecutive patients (age 72.3 ± 9.7 years, EuroSCORE II 11.1 ± 8.9%) underwent reintervention for failed stentless aortic valves (60% porcine, 40% pericardial, 87% sub-coronary, 81% isolated/combined regurgitation). RESULTS: Based on age, EuroSCORE II, the presence of pulmonary hypertension, renal failure, a patent internal mammary artery graft and required concomitant procedures, the heart team assigned 25 patients to reoperation and 27 to valve-in-valve transcatheter aortic valve implantation (ViV-TAVI). Valve implantation was successful in all surgical (24% root replacement) and in 24 transcatheter cases (93% trans-femoral, 56% balloon-expandable). Procedural complications were aortic dissection ( n = 1) during reoperation and coronary obstruction ( n = 4), device malpositioning ( n = 3), deployment of >1 valve ( n = 2) and vascular access site complications ( n = 2) during ViV-TAVI. Thirty-day mortality (10%, three ViV-TAVI patients, two surgical patients, P = 1.0) was associated with preoperative renal failure, >1 concomitant procedure, life-threatening bleeding, coronary obstruction and necessity for prolonged circulatory support. ViV-TAVI was beneficial regarding ventilation time, transfusion requirements and the incidence of sepsis. Overall, functional (94% New York Heart Association Class I/II) and echocardiographic results (indexed effective orifice area 0.95 ± 0.27 cm 2 /m 2 , mean transvalvular gradient 14 ± 6.8 mmHg) were favourable. After ViV-TAVI, aortic regurgitation was mild and moderate in two and three patients. One-year survival was 82.3 ± 5.4% and similar after surgery (83.1 ± 7.7%) and ViV-TAVI (81.5 ± 7.5%, P = 0.76). CONCLUSIONS: Reinterventions for degenerated stentless aortic valves are challenging. Although ViV-TAVI is appropriate in high-risk patients, limitations and potential complications must be considered. Redo surgery has its place in low-risk patients and if concomitant procedures are required.
引用
- Grubitzsch H, Zobel S, Christ T, et al. Redo procedures for degenerated stentless aortic xenografts and the role of valve-in-valve transcatheter techniques. Eur J Cardiothorac Surg. 2017. PMID: 28062549. doi:10.1093/ejcts/ezw397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。